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ORIGINAL ARTICLE
The Effectiveness of Post-Offer Pre-Placement Nerve
Conduction Screening for Carpal Tunnel Syndrome
Ann Marie Dale, PhD, OTR/L, Bethany T. Gardner, OTD, OTR/L, Angelique Zeringue, MS,
Robert Werner, MD, MS, Alfred Franzblau, MD, and Bradley Evanoff, MD, MPH
Objective: We evaluated post-offer pre-placement (POPP) nerve conduc-
tion studies (NCS) for carpal tunnel syndrome (CTS), testing diagnostic
yield and cost-effectiveness. Methods: A total of 1027 newly hired workers
underwent baseline NCS and were followed for an average of 3.7 years for
diagnosed CTS.Measures of diagnostic yield included sensitivity, specificity,
and positive predictive value (PPV). Cost-effectiveness of POPP screening
was evaluated using a range of inputs. Results: Abnormal NCS was strongly
associated with future CTSwith univariate hazard ratios ranging from 2.95 to
11.25, depending on test parameters used. Nevertheless, PPVwas poor, 6.4%
to 18.5%. Cost-effectiveness of POPP varied with CTS case costs, screening
costs, and NCS thresholds. Conclusions: Although abnormal NCS at hire
increases risk of future CTS, the PPV is low, and POPP screening is not
cost-effective to employers in most scenarios tested.
C arpal tunnel syndrome (CTS) is a common work-related upperextremity musculoskeletal disorder and has the longest time
away from work and the highest associated direct costs among up-
per extremitywork-related injuries andmusculoskeletal disorders.1–4
Direct medical costs are estimated to exceed $1 billion per year.1,3
Carpal tunnel syndrome can also cause significant impairment in
functional ability for workers in both work and daily activities.2,5,6
Some employers routinely use post-offer pre-placement (POPP)
screening, including nerve conduction studies (NCS), to identify
workers at higher risk of developing CTS, so that these workers will
not be hired into hand-intensive jobs at higher risk of CTS, thus re-
ducing the employer’s injury rates andworkers’ compensation costs.7
It is difficult to estimate the number of employers currently utilizing
POPP NCS to make hiring decisions; to our knowledge, there are
no published scientific reports describing the prevalence of POPP
testing by employers. Despite a lack of clear scientific evidence that
POPP screening with NCS is sufficiently predictive of future CTS,
this practice seems to be widespread on the basis of publications
in trade journals, advertisements by health care facilities offering
“carpal tunnel testing or screening,”8–17 and promotion by device
manufacturers.
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Studies of active industrial workers have found a high preva-
lence of asymptomatic nerve conduction abnormalities, from 15%
to 20%.18–26 Available studies indicate that asymptomatic workers
with abnormal NCS are at a higher risk of developing CTS than
asymptomatic workers whose NCS are normal.18,27,28 Nevertheless,
the magnitude of the increased risk conferred by nerve conduction
abnormalities, the cost–benefit of doing such screening, and the ef-
fectiveness of different work placement strategies in preventing CTS
all remain to be defined.
Another potential limitation of most existing studies is the
possibility of a survivor bias resulting from selection of subjects
who have worked for years in a hand-intensive industry; these stud-
ies may have evaluated those workers who remained asymptomatic
despite work demands and abnormalities of nerve conduction.29 The
predictive value of NCS may thus be different among job applicants
than among active workers in hand-intensive industries. Only one
study to date has screened new employees at the time of hire and
followed their development of CTS longitudinally. This study by
Franzblau et al28 assessed workers in a single manufacturing plant
who received NCS before hire but were hired regardless of the re-
sults. Results from this study showed that abnormal NCS conferred
a higher risk for a future workers’ compensation claim for CTS;
however, most of the claims came from workers whose screening
NCS were normal at the time of hire, and the cost of worker testing
exceeded the potential savings that would have resulted from not
hiring workers with abnormal NCS.
For the purposes of screening, it is unclear whether it is prefer-
able to measure median nerve latency via sensory nerve latency, mo-
tor nerve latency, or in comparison to ulnar nerve latencies. Different
testing techniques and different placement of electrodes can alter the
results obtained.30–32 Another important issue in screening studies
of asymptomatic persons is the need to define what constitutes an
“abnormal” test result for working populations. The appropriateness
of current normative values is questioned by studies showing higher
prevalence of “abnormal” values among asymptomatic populations
of active workers than among the general population.33,34 It is not
clear whether the populations from which normative values were
drawn are truly representative of the worker populations in which
the tests are being used.
The aim of this study was to determine whether NCS as part
of POPP screening for new hires correctly identifies people at risk
for CTS across a wide range of industries. This study examined the
hypothesis that workers with baseline abnormalities of median nerve
conduction would have a higher incidence of CTS than those with
normal nerve conduction. In addition, we tested how the prediction
yield varied across different case definitions for determining nor-
mal and abnormal NCS. Finally, we estimated the cost–benefit of
screening from the perspective of the employer.
METHODS
The Predictors of CTS Study, is a prospective, longitudi-
nal study that recruited 1107 subjects from eight employers and
three trade unions between July 2004 and October 2006. Sub-
ject recruitment took place during company post-offer screenings,
new employee orientations, or training classes, depending on each
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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employer’s established hiring procedures. Eligible subjects were
newly hired or had become benefits-eligible within the prior 30
days, were at least 18 years of age, worked a minimum of 30 hours
weekly, and were able to speak English. Subjects were excluded if
they had a prior diagnosis of CTS or peripheral neuropathy, were
pregnant at the time of enrollment, or had a contraindication to
nerve conduction testing. Subjects were recruited from both low and
high hand-intensive jobs and represented a range of industries: con-
struction (carpenters, floor layers, and sheet metal workers), health
care (laboratory and hospital technicians), service (food service and
housekeeping), and clerical work (computer and clerical workers).
Detailed information about recruitment and data collection methods
used for this prospective study has been given in several previous
articles.35–38 The Washington University School of Medicine and
the University of Michigan institutional review boards approved this
study. All subjects provided written informed consent and were com-
pensated for their participation.
Data Collection Measures
At baseline, all study subjects received a structured physi-
cal examination of the upper extremities and bilateral NCS. Subjects
also completed surveys at baseline, 6 months, 18months, 36months,
and annually thereafter. These surveys collected demographic and
personal information, work history and physical and psychosocial
work exposures, and health information, including the presence of
upper extremity symptoms. On each survey, subjects were asked
whether they had received a new diagnosis for any medical or mus-
culoskeletal condition, including CTS, in the prior year.
All subjects received NCS of the median and ulnar nerves
across the wrist with the NC-stat automated testing device (Neu-
rometrix Inc, Waltham, MA). This device has shown to have good
criterion validity compared with traditional electrodiagnostic test-
ing methods in studies performed by the manufacturer and in a
study performed by an independent academic group.38–40 Testing
was performed by trained research technicians according to the
manufacturer’s guidelines, using techniques described in detail in
previous publications.38,41 The NC-stat device uses preconfigured,
nerve-specific electrodes with embedded temperature sensors. Elec-
trodes were placed on the wrist with the distal sensors for the median
nerve placed on the third digit and on the fifth digit for the ulnar
nerve studies. The distance between the wrist sensors and distal fin-
ger sensors was recorded by the research technician. Distal motor
latencies (DMLs) and distal sensory latencies (DSLs) were recorded
for each nerve, and the median-ulnar differences for sensory laten-
cies (MUDS) were calculated. Latencies were normalized to a skin
temperature of 32◦C, using the manufacturer’s guidelines. Results
of NCS were given to each participating worker, but this informa-
tion was not provided to participating employers; no hiring or job
placement decisions were made on the basis of NCS or other study
findings.
Statistical Analysis
For this study, the main outcome measure was a diagnosis
of CTS by a health care provider, as reported by the worker on
any follow-up survey, similar to previous studies of national health
surveillance data.42–44 For calculating time to event and time of
follow-up, workers were censored when a diagnosis of CTS was
reported, or at the date of the last questionnaire completed for those
lost to follow-up or for those without a diagnosis of CTS. Presence
or absence of hand symptoms at baseline was not included in our
case definition; in a setting where employment may be contingent on
the results of POPP screening, workers may have an incentive to un-
derreport symptoms. The analysis in this study was designed to most
closely replicate the use of NCS in POPP screening as performed by
employers.
Chi-square analyses and t tests were used to compare themean
values of the demographic and clinical characteristics, job category,
and CTS outcome for workers with normal NCS results at baseline
and workers with any NCS abnormality at baseline, including either
median DML (greater than 4.5 ms), median DSL (greater than 3.5
ms), or MUDS (greater than 0.5 ms).24 To examine the predictive
value of POPP NCS on diagnosis of CTS, bivariate survival analysis
was conducted using time from the baseline survey date to the first
survey date when CTS was reported. Risk factors were reported as
hazard ratios. Significant predictors (α = 0.05) were included in
the multivariable Cox regression model. The Akaike information
criterion was calculated for each NCS parameter separately, and for
the composite outcome of any abnormal NCS, to describe which
NCS test was the best fit for predicting future CTS.
In addition to determining whether baseline NCS was predic-
tive of CTS diagnosis, we also examined whether prediction varied
on the basis of the varying definitions of an “abnormal” NCS result
derived from baseline DML, DSL, and MUDS. We used a range
of thresholds previously used to identify incident CTS in worker
populations and epidemiological studies,24,45,46 to show the range of
sensitivity and specificity values obtained in POPP screening using
different thresholds. We computed measures of diagnostic yield be-
tween future CTS diagnosis and baseline NCS, including sensitivity,
specificity, positive predictive value (PPV), and negative predictive
value. Using different thresholds and NCS tests, we observed how
many new workers would need to be screened to correctly identify
one future CTS case, and how many workers would be incorrectly
identified as a future CTS case. We repeated these analyses for the
right hand only, to determine whether testing only one hand could
be equally predictive as bilateral testing.
On the basis of these measures, we completed a simple cost–
benefit analysis to model a strategy of POPP screening from the
perspective of the employer, and compared a strategy of not screening
versus a strategy of performing POPP NCS and not hiring workers
whose test results were abnormal. In each scenario, we calculated the
number of workers who would need to be screened to attain the same
number of workers initially hired. The no screening strategy incurred
no screening costs at baseline, but we assigned a cost for each case
of CTS occurring while employed by the original employer or trade
union. The POPP NCS strategy was assigned costs for baseline
screening, and costs of future CTS cases that were incurred only for
those subjects screening normal at baseline. Cost–benefit analysis
used cost estimates of screening and workers’ compensation costs
from a previous cost–benefit analysis of POPP screening for CTS.47
Baseline inputs to our model included a cost per case of CTS of
$20,000, to represent the total cost of a claim, including medical and
indemnity costs,48 and a cost of screening of $150. In addition to the
base model, we conducted a sensitivity analysis, varying the cost of
screening and the cost of treatment, to evaluate the degree to which
our model was affected by assumptions for the cost of screening,
the cost of a CTS claim, and NCS test characteristics. Different cost
estimates for screening were based on published reports of actual
screening costs from one employer, which included not only the cost
of NCS screening but also other hiring costs such as drug testing,
medical evaluations, and administrative costs.28 Different treatment
costs were based on published figures for average treatment costs for
work-related CTS claims in Washington and Ohio State.1,49
RESULTS
Of the original 1107 newly hired workers screened in the
Predictors of CTS Study cohort, 1027 (92.8%) completed at least
one follow-up survey. Five subjects were excluded because baseline
NCS results were indeterminate for median DML, DSL, andMUDS.
Of the 1022 subjects remaining, 35 had partially missing NCS data
and were excluded from analyses requiring the missing parameters,
as seen in Tables 1 to 3. Most workers were men (64.5%) with a
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
C© 2014 American College of Occupational and Environmental Medicine 841
Dale et al JOEM  Volume 56, Number 8, August 2014
TABLE 1. Univariate and Adjusted Predictors of Incident Carpal Tunnel Syndrome at Follow-Up Among All Job Categories
CTS (n = 33) No CTS (n = 989) Adjusted HR*
n Mean (SD) Mean (SD) HR (95% CI) P (95% CI) P AIC
Age, yr 1,022 35.9 (10.4) 30.1 (10.2) 1.04 (1.02, 1.07) <0.01 — — —
Body mass index,
kg/m2
1,022 31.4 (7.4) 28.4 (6.3) 1.06 (1.02, 1.10) <0.01 — — —
n (%) n (%)
Male sex 1,022 13 (39.4) 646 (65.3) 0.33 (0.17, 0.67) <0.01 — — —
Any abnormal NCS
findings†‡§
987 20 (60.6) 227 (22.8) 5.42 (2.60, 11.32) <0.0001 5.36 (2.44–11.75) <0.0001 374.4
Median DML > 4.5
ms†§
1,000 12 (36.4) 143 (14.4) 2.95 (1.45, 6.01) <0.01 3.29 (1.50–7.19) <0.01 413.6
Median DSL > 3.5
ms†§
1,008 19 (57.6) 177 (17.8) 6.57 (3.19, 13.54) <0.0001 6.44 (2.99–13.86) <0.0001 370.8
MUDS > 0.5 ms†§ 983 19 (57.6) 126 (12.7) 11.25 (5.22, 24.21) <0.0001 11.36 (4.88–26.43) <0.0001 336.2
*Adjusted for age, sex, and body mass index.
†Temperature and length adjusted.
‡Median DML > 4.5 ms or median DSL >3.5 ms or MUDS >0.5 ms or absent value.
§Thirty-five subjects were excluded due to partially missing nerve conduction data.
AIC, Akaike information criterion; CI, confidence interval; CTS, carpal tunnel syndrome; DML, distal motor latency; DSL, distal sensory latency; HR, hazard ratio; NCS,
nerve conduction study; MUDS, median ulnar sensory latency difference.
mean age of 30.3 years and a mean body mass index (BMI) of
28.5 kg/m2 (Table 4). A quarter of workers had abnormal POPP
NCS at baseline. Subjects with abnormal NCS at baseline were
significantly older and more likely to be men and to work in the
construction trades. The mean length of follow-up for the cohort
was 3.7 (range, 0.4 to 6.2) years. Over the study period, 33 workers
reported having received a diagnosis of CTS, with a mean time to
first report of diagnosis of 2.4 (range, 0.4 to 5.1) years. Workers
with any NCS abnormality at baseline were significantly more likely
to report a diagnosis of CTS at follow-up. The overall incidence
rate of CTS diagnosis in the cohort was 8.7 per 1000 person years
(PYs). The rate of CTS diagnosis was higher among workers with
abnormal POPP NCS versus workers with normal POPP NCS (22.2
cases per 1000 PYs vs 4.0 cases per 1000 PYs, rate ratio of 5.5 [95%
confidence interval: 2.6 to 11.5]).
Baseline NCS abnormality was a statistically significant pre-
dictor of future CTS diagnosis for all nerve test parameters using our
predefined cut points of median DML greater than 4.5 ms, median
DSL greater than 3.5 ms, or MUDS greater than 0.5 ms (Table 1).
Workers with abnormal MUDS were at the highest risk of becom-
ing diagnosed with CTS over the study period, followed by abnormal
medianDSL, anyNCS abnormality, or abnormalmedianDML.Age,
sex, and BMI were statistically significant predictors of CTS diag-
nosis. There were no substantial changes in the hazard ratios of NCS
tests when we repeated these analyses, adjusting for age, sex, and
BMI. Using the Akaike information criterion to describe the good-
ness of fit, MUDS had the lowest Akaike information criterion value
and thus was a better predictor of CTS than the screening parameters
of any NCS abnormality, median DML, or median DSL.
To examine the effect of defining different NCS cut points for
abnormality on the yield of screening, including the PPV and the
number needed to test to avoid 1 future case of CTS, we examined
the sensitivity and specificity for the cut points shown in Table 2.
As expected for a relatively rare condition, specificity and negative
predictive value were high (75.9% to 93.1% and 97.5% to 98.8%, re-
spectively); however, sensitivity was low (36.4% to 65.5%) and PPV
very low (6.4% to 18.5%). The most sensitive cut point, MUDS
greater than 0.5 ms, detected 65.5% of those who would later be di-
agnosed with CTS. Although reasonably sensitive, this measure had
a very poor PPV: only 13.1% of those with an abnormal value based
on this cut point reported a diagnosis of CTS over the study period.
We repeated these analyses using the right hand only; results were
similar to the findings of bilateral testing; as expected, sensitivity
decreased slightly and specificity improved slightly with unilateral
testing.
To assess the preventive effectiveness of POPP NCS for CTS,
we calculated the number of job candidates who would need to be
screened to avoid 1 future case of CTS among the screened work-
force, using the simple methods previously described by de Kort
and van Dijk.50 Using our predefined cut points, the most sensi-
tive screening parameter, MUDS greater than 0.5 ms, detected only
65.5% of those who would later be diagnosed with CTS, and would
have required testing 54 subjects to detect 1 future case of CTS in
the workforce. At the same time, the lower specificity of the MUDS
greater than 0.5ms parameterwould have inappropriately denied em-
ployment to 7 workers among the 54 who would not have developed
CTS despite having an “abnormal” NCS test.
In assessing the validity of POPP NCS for predicting future
CTS, the analyses reported earlier followed the full cohort ofworkers,
including those who changed employers, and recorded all cases of
CTS during the study period (n = 33). We conducted cost–benefit
analysis from the perspective of the employer, and thus only the 23
CTS cases that occurred while a subject screened at baseline was still
working for the original employer and had complete NCS data were
relevant for inclusion in the cost models. In our base case scenario
using the criterion of “any NCS abnormality” at baseline, 987 newly
hired workers were screened with POPP NCS; 247 workers would
have been rejected for hire, a failure rate of 25%. To attain a work
pool of 987 workers who tested normal, a total of 1317 workers
would need to be screened (987 + 247 replacements from failed
screens+ 83 additional replacements because of a continuous failure
rate of 25% among replacement workers screened). Sixteen of the
23 future CTS cases would have been avoided under a screening
strategy, because they occurred in the population of workers testing
abnormal at baseline, using this criterion. Seven of 23 CTS cases
occurred in the 740 workers screening normal at baseline; we used
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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a cumulative incidence rate of CTS in the population screening
normal at baseline to calculate the expected number of cases in a
population of 987 workers screening normal at baseline (10 CTS
cases when using the testing criterion of any NCS abnormality).
These case counts and the number of workers screened were entered
in to our cost model, using base screening costs of $150 per worker
and CTS treatment cost of $20,000 per case, as shown in Table 3. The
NCS failure rate and the number of CTS cases that would have been
avoided varied with the sensitivity of the NCS parameter used as the
screening criterion. Cost–benefit analysis showed that screening was
favored when NCS test sensitivity was high (any abnormal NCS,
DSL, and MUDS) and cost of screening was low ($150). Using the
same low screening cost but a less sensitive NCS measure (median
DML greater than 4.5 ms), a no screening strategy was favored.With
a higher screening cost ($358), modeled to account for the other costs
associated with hiring new workers,28 a no screening strategy was
favored in all models, regardless of NCS parameters. These findings
were also sensitive to changes in treatment cost for CTS. When
the treatment cost for a CTS case was varied ($13,253 and $5605),
using published workers’ compensation data from Ohio for 1999–
2004,49 and Washington State,1 a no screening strategy was favored
for all NCS screening parameters except when using a selection
criteria of MUDS greater than 0.5 ms with the higher Ohio State
costs.
DISCUSSION
The aim of this study was to determine whether NCS per-
formed at the time of hire were predictive of a future CTS diagnosis
among a cohort of workers in various industries. Results showed
that newly hired workers with abnormal baseline NCS were sig-
nificantly more likely to report a CTS diagnosis during the study
period, which is consistent with previous studies.18,27,28 Despite this
finding, the predictive validity of such POPP NCS screening is at
best low or modest. We tested how the prediction yield varied across
different thresholds for defining normal and abnormal NCS and con-
sistently found low PPV across all screening parameters. Post-offer
pre-placement NCS screening seems to be widely used by employ-
ers, but our cost–benefit models of screening conducted from the
perspective of the employer showed that the costs of screening did
not outweigh the savings for CTS cases that would have been avoided
in the majority of scenarios modeled.
The overall rate of CTS in our cohort was 8.7 cases per 1000
PYs, slightly higher than the rate of 7.8 per 1000 PYs reported by
Franzblau et al.28 The slightly higher rate of CTS observed in our
study population may be partly attributable to our case definition of
CTS diagnoses reported by workers rather than accepted workers’
compensation claims for CTS.28 The rates reported both in our study
and in Franzblau et al likely underestimate the true occurrence of
disease because of untreated or unreported cases.33,51 Not all work-
ers who have symptoms are likely to seek treatment, and of those
workers who seek treatment, not all will file a workers’ compensa-
tion claim or have an accepted claim. The slightly higher incidence
rate in this study may also be attributable to differences in the nerve
conduction parameters used to identify abnormalities for workers.
Our rate is based on the screening definition of “any NCS abnor-
mality” (median DSL, DML, or MUDS) at baseline, whereas actual
test results (latencies, amplitudes, or conduction velocities) were not
available in the Franzblau study, and thus prediction models were
based solely on test summaries defined as normal or abnormal. In
addition, our study had a longer mean follow-up time of 3.7 years
versus 2.1 years.28
A potential limitation of existing studies is the possibility of a
survivor bias, resulting from selection of subjects who were working
for years in a hand-intensive industry18,27; these studies may have
evaluated those workers who remained asymptomatic despite heavy
work demands and abnormalities of nerve conduction.29 Jobs in
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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TABLE 4. Demographic and Clinical Characteristics for the Entire Cohort at Baseline and Workers With Normal
and Abnormal Nerve Conduction Studies at Baseline
Entire Cohort Normal NCS* Abnormal NCS*†
Characteristic (n = 1022) (n = 740) (n = 247) P‡
Age, mean (SD), yr 30.3 (10.3) 29.1 (9.6) 34.2 (11.5) 0.0002
Body mass index, mean (SD), kg/m2 28.5 (6.4) 28.0 (6.2) 30.0 (6.8) 0.08
Sex, n (%) 0.03
Women 363 (35.5) 277 (38.4) 74 (30.0)
Men 659 (64.5) 463 (62.6) 173 (70.0)
Industry, n (%) <0.0001
Construction 424 (41.5) 281 (38.0) 133 (53.9) —
Clerical 366 (35.8) 308 (41.6) 43 (17.4) —
Service/technical 232 (22.7) 151 (20.4) 71 (28.7) —
Diagnosis of CTS, n 33 11 20 <0.0001
PYs of follow-up 3,777.5 2,733.0 900.3 —
Diagnosis of CTS/1000 PYs 8.7 4.0 22.2 —
*Thirty-five subjects were excluded because of partially missing NCS data.
†Temperature and length adjusted, absent values considered abnormal. Abnormal NCS = Any of the following: median distal motor latency greater than 4.5
ms or median distal sensory latency greater than 3.5 ms or median-ulnar sensory latency difference greater than 0.5 ms.
‡Used t tests for continuous data and chi-square tests for categorical data, comparing those with normal and abnormal NCS at baseline.
CTS, carpal tunnel syndrome; NCS, nerve conduction study; PYs, person years.
hand-intensive industries often have high turnover rates, creating a
natural selection bias against workers at greater risk of developing
CTS. This study and that of Franzblau et al28 avoid this potential
bias that the predictive value of NCS may be different among job
applicants than among active workers in hand-intensive industries,
and thus more closely models the use of NCS as a screening tool
during POPP testing. Results from this study included workers from
a wide variety of industries and employers, while Franzblau’s study
included workers from a single employer.
To determine whether the prediction yield of screening for fu-
ture CTS cases could be improved, we evaluated six definitions of an
“abnormal” NCS result from baseline DML, DSL, and MUDS, us-
ing published thresholds previously used inworking populations.45,46
Our results showed that the percentage of future CTS cases that were
correctly predicted was highly dependent on the definition used to
define an abnormal screening result. The sensitivity and specificity
and positive and negative predictive values of POPP NCS have var-
ied, in part because different criteria were used to define normal and
abnormal NCS measures.18,28 The increased risk of CTS diagnosis
in our study varied widely, depending on the measure chosen to de-
fine an abnormal result from a hazard ratio of 2.95 (95% confidence
interval: 1.45 to 6.01; P < 0.01) for median DML (greater than 4.5
ms) to 11.25 (95% confidence interval: 5.22 to 24.21; P < 0.0001)
for abnormal MUDS (greater than 0.5 ms). As with any diagnostic
test, there are explicit trade-offs between sensitivity and specificity
as seen with use of different criteria for defining abnormal NCS. As
parameter cut points used to predict the outcome of future CTS di-
agnosis were made more specific, the employers in the study would
have assumed more risk of potentially hiring workers with greater
risk of developing CTS, whereas when the cut points were more
sensitive, more healthy workers would have been inappropriately ex-
cluded from employment. Our study showed very different results
between different nerve tests and different criteria for defining ab-
normality. Carpal tunnel syndrome POPP screening is often based
on testing only the median nerve; in this study, we found the highest
sensitivity and specificity using the median ulnar difference. In our
experience, POPP testing programs in industry have not formally
considered the effects of different cut points or nerve conduction
testing techniques in assessing the likely yield and cost–benefit of
their screening programs nor have such programs acknowledged the
very low PPV of POPP testing.
Post-offer pre-placement screening with NCS seems to be
widely used by employers, but only two published studies have eval-
uated its cost–benefit to employers. Evaluation of POPP screening
by using cost data from amanufacturing plant28 found that the cost of
screening outweighed potential savings from averting workers’ com-
pensation costs for CTS. A cost–benefit modeling study47 found that
POPP screening for CTS would not be cost-beneficial for most em-
ployers, though could be cost-beneficial under circumstances where
there was a high cost per case and high incidence of CTS. Using these
published models, we compared the cost of screening the workers in
our cohort and not hiring those with abnormal baseline NCS versus a
policy of no screening. Our results were consistent with these previ-
ous studies, showing that POPP NCS screening would not have been
cost-beneficial to the employer in most screening scenarios. When
the cost of screening was high, a no screening strategy was favored in
all cases. As Franzblau et al28 described, there are a number of other
potential costs associated with screening in addition to a nerve con-
duction test, which will vary depending on each employer’s hiring
practices. These costs may include a medical physical examination,
drug test (which may or may not be done concurrently with other
POPP screening), and administrative costs associated with new hire
paperwork and orientation. In addition, we assigned the same cost of
screening regardless of NCS parameter; however, screening parame-
ters that require testing of both the median and ulnar nerves (MUDS)
would likely cost more than median nerve testing only (DML and
DSL). Our simplified cost model did not account for screening costs
in subsequent years of hiring to replace workers lost to turnover and,
thus, may not have fully captured costs of pursuing a POPP screening
strategy.
Cost of treatment for CTS is also highly variable. A 2005
study of work-related CTS claims in Washington State1 found a
median cost per claim of $5605 over a 5-year period, though costs for
individual cases ranged from $359 to $79,265, depending onwhether
surgery was performed and when the CTS diagnosis occurred in the
course of the claim. Our base cost of $20,000 per diagnosed case is
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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very likely to be an overestimate of the costs of CTS to employers,
because not all diagnosed cases would be claimed under workers’
compensation and not all would be surgical cases. The lower costs
seen in Ohio and Washington State are more likely to reflect true
costs of CTS claims under workers’ compensation.
The main limitation of this study was the use of self-reported
CTS diagnosis as the outcome. Because this study was designed to
replicate employer practices, CTS diagnosis was a more appropriate
outcome than an epidemiological case definition, which would have
included workers who had symptoms and abnormal NCS findings
but who never sought treatment or filed a workers’ compensation
claim. A similar case definition of self-reported CTS has been used
in several previous studies of national health surveillance data.42–44
Survival models were censored at survey date because the actual
date of diagnosis was not available. The use of an absolute latency
for defining an abnormal NCS consistent with CTS has been criti-
cized because many factors such as age, temperature, comorbidities,
and BMI can influence the absolute latency of the median nerve.45
Comparison on the median and ulnar latencies controls for these
confounding factors, and our analysis demonstrated that this model
was the strongest predictor of future CTS. We included all three
definitions of abnormal NCS because they are still widely used in
clinical practice.
Our model showed that screening could be favorable only
if the average treatment cost was high and the screening cost was
low. As discussed in other articles,47,50 for screening to be cost-
beneficial the prevalence of the disorder must be high among new
hires and the incidence high after hire. High employee turnover
also increases the cost of screening and decreases potential em-
ployer cost savings, because screened workers may leave em-
ployment before developing the disease of interest.47 Our re-
sults highlight the sensitivity of the cost–benefit model to the
cost of screening, the cost per CTS case, and the sensitivity of the
screening test. This relationship highlights the need for employers
who utilize POPP screening to pick appropriate test cut points for
their workforce rather than a clinical or general population. Finally,
the cost–benefit of screening should be considered within the larger
societal context of not hiring otherwise qualified workers. Because
of the low PPV of POPP NCS screening for future CTS, data from
this study showed that each workplace case of CTS avoided for the
employer would come at the cost of inappropriate denial of employ-
ment or job placement for 4 to 15 workers who would not develop
CTS during the course of their employment. This raises another con-
sideration for employers, the several court cases claiming that em-
ployers violated the Americans with Disabilities Act or other laws
when applicants were excluded from production jobs on the basis of
POPP testing for future risk of CTS. Although some past cases were
settled in favor of the employer (Equal Employment Opportunity
Commission vs Woodbridge Corporation, 8th Circuit No. 01-L045,
August 24, 2001; Equal Employment Opportunity Commission vs
Rockwell International Corporation, 7th Circuit Nos. 00-1897 and
00-2034, March 8, 2001), the Equal Employment Opportunity Com-
mission recently won a discrimination case against an employer who
excluded a worker from employment on the basis of perceived risk
of future CTS.52 Although this case was based on violation of the
Genetic Information Nondiscrimination Act, at least one other law-
suit in progress addresses discriminatory aspects of POPP screening
by median NCS.
CONCLUSIONS
Although abnormal NCS at the time of hire is strongly as-
sociated with increased risk of future CTS, the predictive value of
such testing is poor, even when using optimal criteria as screening
thresholds. The cost of screening and rejecting large numbers of
healthy workers from employment is high and, in most cases, seems
to outweigh potential employer cost savings from reducing the in-
cidence of CTS in a given workforce. The social costs of rejecting
otherwise qualified healthy workers from employment should also
be considered. In all scenarios described earlier, the vast majority
of workers with “abnormal” screening results did not develop CTS
and, thus, would be inappropriately placed or denied employment
on the basis of a test with demonstrably poor PPV for future dis-
ease. Post-offer pre-placement screening for CTS seems to be widely
used, despite ongoing uncertainty about ideal screening procedures,
appropriate cut points for screening versus diagnosis of clinical
median neuropathy, and cost–benefits of the procedure for employ-
ers. Employers should be cautious in implementing any broadworker
screening programs without careful consideration of the costs and
benefits of such programs. Available evidence shows that POPP
screening for CTS is poorly predictive of future disease, and pub-
lished studies to date have failed to show that this practice is effec-
tive. Occupational health professionals should not endorse screen-
ing programs that are not based on evidence of benefit to workers’
health.
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